Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Anaplastic Lymphoma Kinase”

149 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 149 results

Early research (Phase 1)Looking for participantsNCT07001384
What this trial is testing

Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)

Who this might be right for
Anaplastic Lymphoma KinaseAnaplastic Large Cell Lymphoma
Memorial Sloan Kettering Cancer Center 30
Large-scale testing (Phase 3)Study completedNCT00932893
What this trial is testing

An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Pfizer 347
Large-scale testing (Phase 3)Active Not RecruitingNCT02201992
What this trial is testing

Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

Who this might be right for
ALK Gene RearrangementALK Gene TranslocationALK Positive+5 more
ECOG-ACRIN Cancer Research Group 166
Post-approval studies (Phase 4)UnknownNCT03707847
What this trial is testing

Crizotinib Combined With Etoposide Capsule Followed by Auto-HSCT for Relapsed and Refractory ALK+ ALCL

Who this might be right for
ALK-Positive Anaplastic Large Cell Lymphoma
Mingzhi Zhang 20
Not applicableLooking for participantsNCT04592523
What this trial is testing

Usage of Brigatinib in the Treatment of Adult Participants for Approved Indications In South Korea

Who this might be right for
Carcinoma, Non-Small-Cell LungAnaplastic Lymphoma Kinase
Takeda 257
Testing effectiveness (Phase 2)Active Not RecruitingNCT05200481
What this trial is testing

Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK)

Who this might be right for
Non Small Cell Lung CancerALK Gene Mutation
Intergroupe Francophone de Cancerologie Thoracique 110
Early research (Phase 1)Active Not RecruitingNCT02321501
What this trial is testing

Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer

Who this might be right for
ALK PositiveLocally Advanced Malignant Solid NeoplasmMetastatic Malignant Solid Neoplasm+3 more
M.D. Anderson Cancer Center 37
Testing effectiveness (Phase 2)Looking for participantsNCT06378892
What this trial is testing

Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on Lorlatinib

Who this might be right for
Non Small Cell Lung Cancer MetastaticALK Gene Mutation
Centro di Riferimento Oncologico - Aviano 45
Testing effectiveness (Phase 2)Active Not RecruitingNCT02568267
What this trial is testing

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

Who this might be right for
Breast CancerCholangiocarcinomaColorectal Cancer+13 more
Hoffmann-La Roche 534
Early research (Phase 1)Looking for participantsNCT05142189
What this trial is testing

Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
BioNTech SE 320
Early research (Phase 1)Study completedNCT01742286
What this trial is testing

Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)

Who this might be right for
ALK-activated Tumors
Novartis Pharmaceuticals 83
Large-scale testing (Phase 3)Active Not RecruitingNCT06569420
What this trial is testing

Study Of Comparing SAF-189s With Crizotinib In First Line ALK-Positive Advanced and Metastatic NSCLC

Who this might be right for
Non-Small Cell Lung CancerALK-positiveSAF-189s
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. 275
Early research (Phase 1)UnknownNCT04671849
What this trial is testing

An Open Label, Multi-center, Phase I Clinical Study to Evaluate the Safety, Effectiveness and Pharmacokinetic Characteristics of SIM1803-1A in Patients With Locally Advanced/Metastatic Solid Tumors With NTRK, ROS1 or ALK Gene Fusion Mutations.

Who this might be right for
Advanced or Metastatic Solid Tumors With NTRK, ROS1 or ALK Gene Fusion
Jiangsu Simcere Pharmaceutical Co., Ltd. 243
Testing effectiveness (Phase 2)Ended earlyNCT02465528
What this trial is testing

Ceritinib Rare Indications Study in ALK+ Tumors

Who this might be right for
Tumors With Aberrations in ALKAnaplastic Large Cell LymphomaInflammatory Myofibroblastic Tumor+1 more
Novartis Pharmaceuticals 22
Early research (Phase 1)Ended earlyNCT04800822
What this trial is testing

PF-07284892 in Participants With Advanced Solid Tumors

Who this might be right for
Solid Tumor
Pfizer 53
Not applicableNot Yet RecruitingNCT06736561
What this trial is testing

Real-world Clinical Study on the Efficacy and Safety of Ensartinib As Neoadjuvant Treatment for Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung Cancer (NSCLC) Patients.

Who this might be right for
ALK PositiveEnsartinibNSCLC+1 more
Harbin Medical University 100
Early research (Phase 1)Study completedNCT00697346
What this trial is testing

Study of MLN8237 in Participants With Advanced Hematological Malignancies

Who this might be right for
B-cell Follicular LymphomaB-cell Marginal Zone LymphomaDiffuse Large B-cell Lymphoma+10 more
Millennium Pharmaceuticals, Inc. 58
Testing effectiveness (Phase 2)Study completedNCT01871805
What this trial is testing

Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-Small Cell Lung Cancer
Hoffmann-La Roche 134
Early research (Phase 1)Ended earlyNCT01121588
What this trial is testing

Studying An Investigational Drug Crizotinib (PF-02341066) In Non Non-Small Cell Lung Cancer Tumors That Are Positive For Anaplastic Lymphoma Kinase (ALK)

Who this might be right for
Neoplasms Malignant
Pfizer 44
Large-scale testing (Phase 3)Study completedNCT02604342
What this trial is testing

Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Participants Previously Treated With Platinum-Based Chemotherapy and Crizotinib

Who this might be right for
Non-small Cell Lung Cancer
Hoffmann-La Roche 119
Load More Results